Brokerages expect that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce sales of $13.37 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $16.58 million and the lowest estimate coming in at $10.17 million. Lexicon Pharmaceuticals reported sales of $25.21 million during the same quarter last year, which would suggest a negative year over year growth rate of 47%. The company is scheduled to issue its next earnings report on Thursday, May 2nd.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $93.68 million for the current year, with estimates ranging from $58.47 million to $176.21 million. For the next year, analysts anticipate that the company will report sales of $103.38 million, with estimates ranging from $40.23 million to $152.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The firm’s revenue for the quarter was down 49.7% compared to the same quarter last year.
NASDAQ:LXRX traded down $0.08 on Monday, reaching $5.58. The company’s stock had a trading volume of 645,697 shares, compared to its average volume of 906,339. Lexicon Pharmaceuticals has a 12-month low of $4.25 and a 12-month high of $13.97. The company has a market capitalization of $593.00 million, a P/E ratio of -4.89 and a beta of 0.71.
Hedge funds have recently bought and sold shares of the stock. Pegasus Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $66,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $73,000. CWM Advisors LLC raised its holdings in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares during the period. D.A. Davidson & CO. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $87,000. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares during the period. Hedge funds and other institutional investors own 99.16% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: Why is a lock-up period needed for an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.